KIDNEY TRANSPLANTATION

  • Coronary artery disease in renal transplant recipients
    William E. Braun, MD and Thomas H. Marwick, MD
    Cleveland Clinic Journal of Medicine September 1994, 61 (5) 370-385;

    Screening for coronary artery disease before transplantation can identify high -risk patients and save lives and money.

  • Azathioprine vs cyclosporine in recipients of HLA-identical renal allografts
    Inderbir S. Gill, MD, Ernest E. Hodge, MD, Andrew C. Novick, MD, Stevan B. Streem, MD, William E. Braun, MD and Lata Paranandi, MSHP
    Cleveland Clinic Journal of Medicine May 1994, 61 (3) 206-210;

    These two agents produce equally satisfactory outcomes in this immunologically favored group. The need for continued steroid therapy in these patients requires further study.

  • Initial studies with FK506 in renal transplantation
    Mark L. Jordan, MD, Ron Shapiro, MD, John Fung, MD, PhD, Andreas Tzakis, MD, Saturo Todo, MD, Shimon Kusne, MD, Jake Demetrius, MD, Thomas R. Hakala, MD and Thomas E. Starzl, MD, PhD
    Cleveland Clinic Journal of Medicine September 1991, 58 (5) 444-446;

    Advantages of this immunosuppressive agent include relatively few side effects and high potency, eliminating the need for steroids in some patients.